Evidence map›Paper›PMID 39758817›Full record

ArticleiScience2025

The HIP mouse and all of its organs are completely invisible to allogeneic immune cells.

Xiaomeng Hu, Kathy White, Ari G Olroyd, Chenyan Wang, Carolin B Caruso, Corie Gattis, Chi Young, Andrew J Connolly, Tobias Deuse, Sonja Schrepfer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Hypoimmune platforms: from rejection to immune evasion and regulatory implications.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaomeng HuSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Kathy WhiteSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Ari G OlroydSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Chenyan WangSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Carolin B CarusoSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Corie GattisSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Chi YoungSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.
Andrew J ConnollyDepartment of Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.
Tobias DeuseDepartment of Surgery, Division of Cardiothoracic Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California, San Francisco, San Francisco, CA, USA.
Sonja SchrepferSana Biotechnology Inc., 1 Tower Place, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoimmune (HIP) allogeneic cell therapeutics hold the promise to allow off-the-shelf treatments for a broad patient population. Our HIP approach includes the depletion of major histocompatibility complex (MHC) class I and II molecules and the overexpression of Cd47. Here, we report the engineering of HIP mice that stably exhibit the HIP phenotype in all cell types. Parabiosis experiments were designed to broadly assess immune evasiveness of all HIP blood cells in fully allogeneic BALB/c mice. HIP blood cells did not induce any immune response and achieved stable engraftment in BALB/c mice. Parabiosis experiments with irradiated HIP mice served as a model for full-body transplantation. There was no measurable cellular or antibody response in immunocompetent, allogeneic BALB/c parabionts. Transplantation of HIP islets into diabetic, allogeneic BALB/c mice reliably treated diabetes in all animals. Together, these data suggest that all allogeneic tissues can be HIP engineered and HIP cell therapy may be envisioned for many more indications.

Indexed as

Biological sciencesImmune responseImmunologyNatural sciences

Identifiers

PMID39758817
PMCPMC11699395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.